Forendo Pharma (Organon)

One of the largest biotech companies in Finland is Forendo Pharma. It is a biopharmaceutical company focused on the development of innovative treatments for endometriosis and other hormone-driven inflammatory diseases. The company is based in Finland and was founded in 2013.

Endometriosis, a disorder of the uterus that results in excruciating pain and infertility, is treated by Forendo Pharma. Small molecule medication candidates are being developed by the company that is intended to work locally rather than altering hormone levels throughout the body as do current therapies. Phase I trials for the most advanced program is now taking place. Forendo Pharma is dedicated to addressing the unmet medical needs in this field by developing novel therapeutics targeting the underlying mechanisms of endometriosis.

Forendo Pharma's approach involves targeting tissue-specific enzyme systems that are involved in the production and metabolism of hormones, particularly estrogen. By modulating these enzyme systems, the company aims to develop treatments that can reduce the inflammation and associated symptoms of endometriosis.

In order to focus on enhancing women's health throughout their lives, Organon was created as a spin-off from Merck, which is known as MSD outside of the United States and Canada. In December 2021, Organon announced the completion of the acquisition of Forendo Pharma

Headquarters: Turku, Western Finland, Finland
Founded: 2013
Website: https://www.organon.com/news/organon-to-acquire-forendo-pharma/